← Clinical Trial Results
StrokePhase 3RandomizedNCT01661322

TARDIS: Complete Statistical Analysis of Triple Antiplatelets in Ischaemic Stroke

An independent statistical review of the randomized phase 3 TARDIS trial evaluating triple antiplatelet therapy with aspirin, dipyridamole, and clopidogrel after ischaemic stroke.

ClinicalTrials.gov identifier: NCT01661322
Scope of this record

This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.

1. Trial at a Glance

TARDIS was a phase 3 randomized parallel-group clinical trial evaluating triple antiplatelet therapy after ischaemic stroke.

3096
Enrollment
3
Antiplatelet agents
90 days
Primary endpoint time frame
2
Study arms
FeatureTARDIS
PhasePhase 3
StatusTerminated
Start date2009-04
Primary completion date2017-09
Lead sponsorUniversity of Nottingham
ConditionStroke
AllocationRandomized
Design modelParallel
MaskingSingle
Primary purposeTreatment

2. Clinical Question

The clinical question addressed by TARDIS was whether treatment involving aspirin, dipyridamole, and clopidogrel could be evaluated against the comparator strategy in patients with stroke using a randomized clinical trial framework.

Population

Patients with stroke.

Intervention

Aspirin, dipyridamole, and clopidogrel.

Comparator

The randomized comparator arm.

Primary question

Comparison of ordinal stroke severity at 90 days.

3. Trial Design

Randomization
3096 patients
Parallel groups
2 arms
Single masking
Phase 3
Assessment
90 days
Intervention

Aspirin, dipyridamole, and clopidogrel.

Design

Randomized parallel-group treatment study.

4. Endpoints

EndpointDefinitionTime frame
Primary outcomeOrdinal stroke severity at 90 days using a 5-level ordinal stroke and TIA scale ordered by severity using the modified Rankin Scale (mRS): fatal stroke / severe non-fatal stroke (mRS 2-5) / mild stroke (mRS 0,1) / TIA / no stroke-TIA.90 days

5. Planned Analysis

The registry identifies the primary outcome as an ordinal stroke severity measure rather than a simple binary event. Ordinal outcomes preserve information about severity categories and can provide greater statistical efficiency than collapsing outcomes into only stroke versus no stroke.

Ordinal outcome analysis

For an ordered categorical endpoint, statistical approaches commonly model the probability distribution across severity levels while respecting the ordering between categories.

The registry describes the outcome scale as an approach that allows smaller sample sizes compared with binary outcomes such as stroke/no stroke.

Registry status: Results and formal statistical analyses have not been posted to ClinicalTrials.gov.

6. Statistical Methodology

Ordinal analysis

The primary endpoint uses ordered categories of stroke severity. Unlike a binary endpoint, an ordinal analysis uses the full ranking of outcomes, distinguishing between different degrees of disability and clinical status.

Why ordinal outcomes matter

Converting an ordinal scale into a binary outcome can discard information. For example, severe disability, mild disability, and no event are clinically different states. Ordinal methods attempt to retain these distinctions.

Randomization

Random allocation is designed to balance measured and unmeasured factors between treatment groups, allowing differences in outcomes to be interpreted within the randomized comparison.

7. Statistical Methods Explained

Why use an ordinal stroke severity outcome?

An ordinal endpoint captures the degree of neurological outcome rather than only whether a stroke occurred. This can increase statistical efficiency when clinically meaningful severity categories are available.

How is an ordinal endpoint different from a binary endpoint?

A binary endpoint has two possible outcomes. An ordinal endpoint contains ordered categories, allowing analysis of the distribution across levels of severity.

What does the modified Rankin Scale contribute?

The modified Rankin Scale provides an ordered framework for describing disability after stroke, allowing outcomes to be grouped by increasing severity.

Why does randomization matter?

Randomization creates comparable groups at baseline on average, reducing confounding in the treatment comparison.

Why are confidence intervals important?

Confidence intervals describe uncertainty around estimated effects. They provide information about the precision of an estimate rather than the probability that a particular value is true.

8. Limitations

9. Why This Trial Matters Statistically

TARDIS is a useful teaching example because it illustrates how clinical trials can use ordinal endpoints to preserve clinically meaningful information rather than reducing outcomes to a simple yes/no event.

ConceptHow it appears in TARDIS
RandomizationRandomized phase 3 parallel-group design.
Ordinal outcomesPrimary outcome based on ordered stroke severity categories.
Modified Rankin ScaleFramework for ordered disability severity assessment.
Clinical interpretationSeparating statistical modeling from clinical meaning of severity categories.

10. Sources